Drug recall · February 12, 2014
Hydralazine HCL Tablets recall
Why: Failed Impurities/Degradation Specifications:There is a potential for the tablets to be out of specification for impurities throughout shelf life.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Hydralazine HCL Tablets, USP, 50 mg in a single blister package, Rx only, Manufactured in Czech Republic by: Teva Czech Industries s.r.o. Opava-Komarov, Czech Republic, Distributed by Goldline Laboratories, Sellersville, PA, NDC 00182-0555-89 (carton) and 00182-0555-00 (single blister).
- Lots / codes
Lot # 6A201018VA; Exp. 01/14.
- Quantity
- 112,800 tablets
- Company
- Teva Pharmaceuticals USA, Horsham, PA
- Distribution
- Nationwide
- Initiated
- December 18, 2013 · Voluntary: Firm initiated
- Classified
- February 4, 2014
- Reported
- February 12, 2014
- Ended
- October 22, 2014
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Hydralazine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.